Skip to search formSkip to main contentSkip to account menu

TAK 442

Known as: TAK-442, TAK442 
National Institutes of Health

Related topics

Related topics

1 relation

Broader (1)

Letaxaban

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2012
Review
2012
Novel oral anticoagulants in the treatment of acute coronary syndromes: is there any room for new anticoagulants?
Thrombosis plays a key role in the pathophysiology of acute coronary syndromes (ACS). The management of patients with ACS… 
2011
2011
Effects of Fondaparinux and a Direct Factor Xa Inhibitor TAK-442 on Platelet-associated Prothrombinase in the Balloon-injured Artery of Rats
Endothelial damage triggers platelet adhesion and platelet-associated prothrombinase formation at the point of injury, resulting… 
2010
2010
Antithrombotic and Anticoagulant Profiles of TAK-442, a Novel Factor Xa Inhibitor, in a Rabbit Model of Venous Thrombosis
The anticoagulant and antithrombotic profiles of TAK-442, a direct factor Xa (FXa) inhibitor, were investigated. TAK-442 showed… 
2010
2010
Pharmacokinetic and Pharmacodynamic Modeling of the Relationship Between TAK-442 Exposure and Clinical Outcome In Patients Undergoing Elective Knee Arthroplasty
Abstract 3326 Introduction: TAK-442 is an oral direct factor Xa (fXa) inhibitor currently in clinical development for the… 
2009
2009
Discovery of a tetrahydropyrimidin-2(1H)-one derivative (TAK-442) as a potent, selective, and orally active factor Xa inhibitor.
Coagulation enzyme factor Xa (FXa) is a particularly promising target for the development of new anticoagulant agents. We… 
Review
2009
Review
2009
Factor Xa inhibitors
Summary Oral factor Xa (FXa) inhibitors are a promising alternative to current anticoagulants. This paper reviews the latest… 
2009
2009
Phase II Dose-Finding Study with TAK-442, An Oral Factor Xa Inhibitor, in Patients Undergoing Elective Knee Arthroplasty.
Abstract 170 TAK-442 is an oral, selective, direct competitive inhibitor of activated factor X (fXa). This phase 2, multicenter… 
2009
2009
Absence of Pharmacodynamic or Pharmacokinetic Interactions When TAK-442, An Oral, Direct Factor Xa Inhibitor, Is Coadministered with Aspirin or Clopidogrel.
Abstract 4175 Introduction TAK-442 is a novel orally active, direct Factor Xa (fXa) inhibitor in clinical development for the… 
2008
2008
Effects of TAK-442, a Direct FXa Inhibitor, and Fondaparinux on Platelet-Associated Prothrombinase in the Balloon Injured Artery of Rats
PCI patients routinely experience arterial injury during balloon angioplasty and stent deployment. At the injured arterial site… 
2008
2008
Differential Effects of TAK-442, a Factor Xa Inhibitor, and Ximelagatran, a Thrombin Inhibitor, on Bleeding: Possible Role of Differences in Effects on Factor V-Mediated Feedback on Blood Coagulation…
Thrombin generation serves to amplify the coagulation cascade via positive feedback activation of factor V (FV) and factor VIII… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)